U.S – Dr. Namandjé N. Bumpus, the current Chief Scientist, is slated to take the helm as the U.S. Food and Drug Administration’s (FDA’s) next Principal Deputy Commissioner upon the retirement of Janet Woodcock, M.D. in early 2024.
The revelation, confirmed by FDA Commissioner Robert M. Califf, M.D., heralds a new era for the agency, marked by innovative initiatives and a commitment to transparent public health communication.
In an exclusive FDA staff email shared by Assistant Commissioner for Media Affairs, Michael Felberbaum, Dr. Bumpus’ elevation is portrayed as a testament to her visionary leadership.
Known for championing plain language and truth-telling in public health communications, Dr. Bumpus has been instrumental in elevating FDA’s research, science, and innovation efforts since assuming the role of Chief Scientist in 2022.
A linchpin of Dr. Bumpus’ agenda as Principal Deputy Commissioner will be the reorganization of the Human Foods Program, under the stewardship of the new FDA Deputy Commissioner for Human Foods, Jim Jones.
The overhaul aims to create a novel model for the Office of Regulatory Affairs (ORA), ensuring streamlined and effective regulatory processes.
Before her tenure at the FDA, Dr. Bumpus carved a distinguished career at the Johns Hopkins University School of Medicine, where she served as the E.K. Marshall and Thomas H. Maren Professor and chair of the Department of Pharmacology and Molecular Sciences.
Recognized for her groundbreaking research in drug metabolism, pharmacogenetics, bioanalytical chemistry, and infectious disease pharmacology, Dr. Bumpus brings a wealth of expertise to her new role.
With a bachelor’s degree in Biology from Occidental College and a doctorate in pharmacology from the University of Michigan, Dr. Bumpus further honed her skills through a postdoctoral fellowship at The Scripps Research Institute in La Jolla, California.
Her accolades include the prestigious Presidential Early Career Award for Scientists and Engineers, a testament to her contributions to the field.
Dr. Bumpus’ commitment extends beyond her role at the FDA; she currently presides as the president of the American Society for Pharmacology and Experimental Therapeutics. Notably, she served as chair of the U.S. National Institutes of Health (NIH) Xenobiotic and Nutrient Disposition and Action study section.
Her exceptional contributions to the scientific community have been recognized with honors such as the Leon I. Goldberg Award, the James Gillette Award, and the John J. Abel Award in Pharmacology.
As an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine, Class of 2022, Dr. Bumpus stands among the elite in the realms of health, science, and medicine.